PHARMACOGENOMICS IN THE CONTEXT OF AFRICA


Publications

  1. Röhrich C*, Drögemöller B*, Ikediobi O, van der Merwe L, Grobbelaar N, Wright G, McGregor N, Warnich L. CYP2B6*6 and CYP2B6*18 predict long-term efavirenz exposure measured in hair samples in HIV-positive South African women. AIDS Res Hum Retroviruses. 2016;32(6):529-38. *These authors contributed equally to this publication.

  2. Dodgen T, Drögemöller B, Wright G, Warnich L, Steffens F, Cromarty D, Alessandrini M, Pepper M. Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a demographic South African population. Pharmacogenomics. 2015;16(12):1343-54.

  3. Drögemöller B, Wright G, Warnich L. Considerations for rare variants in drug metabolism genes and the clinical implications. Expert Opin Drug Metab Toxicol. 2014;10(6):873-84.

  4. Drögemöller B*, Plummer M*, Korkie L*, Agenbag G, Dunaiski A, Niehaus D, Koen L, Gebhardt S, Schneider N, Olckers A, Wright G, Warnich L. Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Gene. 2013;4:17. *These authors contributed equally to this publication.

  5. Dodgen T, Hochfeld W, Fickl H, Asfaha S, Durandt C, Rheeder P, Drögemöller B, Wright G, Warnich L, Labuschagne D de J, van Schalkwyk A, Gaedigk A, Pepper M. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet. 2013;14:20.

  6. Drögemöller B, Wright G, Niehaus D, Emsley R, Warnich L. Whole genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics. 2011;12:1717-28.

  7. Warnich L, Drögemöller B, Pepper M, Dandara C, Wright G. Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation. Curr Pharmacogenomics Person Med.  2011;9:191-207.

  8. Drögemöller B, Wright G, Niehaus D, Koen L, Malan S, Da Silva D, Hillermann-Rebello R, La Grange A, Venter M, Warnich L. Characterization of the genetic profile of CYP2C19 in two South African populations.Pharmacogenomics. 2010;11:1095–103.

  9. Wright G, Niehaus D, Drögemöller B, Koen L, Warnich L. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet. 2010;74:340-50.

Awards

  1. Best Oral Presentation at the Biological Psychiatry Congress for presentation entitled Personalized genomic profiles: applications in African psychiatric pharmacogenetics (2011)

  2. Harry Crossley Foundation Bursary for project entitled Detection of sequence diversity in the CYP2C19 gene of Xhosa South African individuals: An analytical and comparative study including in silico and functional analysis of the 5’ flanking region (2008-2009)

  3. Stellenbosch University Faculty of Health Sciences’ Annual Academic Day 
    Young Researcher Winning Oral Presentation (Category <35 years) for presentation entitled CYP2C19 sequence diversity: A missing ingredient in the optimal treatment plans of South African individuals (2009)

  4. South African National Research Foundation Grant-Holder Bursary for project entitled Detection of sequence diversity in the CYP2C19 gene of Xhosa South African individuals: An analytical and comparative study including in silico and functional analysis of the 5’ flanking region (2008)

  5. South African National Research Foundation Prestige Programme for project entitled Detection of sequence diversity in the CYP2C19 gene of Xhosa South African individuals: An analytical and comparative study including in silico and functional analysis of the 5’ flanking region (2007)

  6. Stellenbosch University Honours Merit Bursary for project entitled Identification of genetic variants in the promoter region and exons 1-4 of the CYP2C19 gene in Xhosa individuals (2007)